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An intact immune system is essential to prevent the development and progression of neoplastic cells in a process termed immune
surveillance. During this process the innate and the adaptive immune systems closely cooperate and especially T cells play an
important role to detect and eliminate tumor cells. Due to the mechanism of central tolerance the frequency of T cells displaying
appropriate arranged tumor-peptide-speciﬁc-T-cell receptors is very low and their activation by professional antigen-presenting
cells, such as dendritic cells, is frequently hampered by insuﬃcient costimulation resulting in peripheral tolerance. In addition,
inhibitory immune circuits can impair an eﬃcient antitumoral response of reactive T cells. It also has been demonstrated that
large tumor burden can promote a state of immunosuppression that in turn can facilitate neoplastic progression. Moreover, tumor
cells, which mostly are genetically instable, can gain rescue mechanisms which further impair immune surveillance by T cells.
Herein, we summarize the data on how tumor cells evade T-cell immune surveillance with the focus on solid tumors and describe
approaches to improve anticancer capacity of T cells.
1.Introduction
The theory of immune surveillance was introduced in the
early 1900s by Ehrlich, who hypothesized that one critical
function of the immune system was to detect and elimi-
nate tumors from the host [1]. As a logical consequence,
tumor development should more likely occur when the
innate and/or adaptive immunity is impaired or repressed.
This hypothesis could be tested in a variety of knock-out
mice that were deﬁcient in one or more components of
the innate or adaptive immune system. And indeed, the
elimination of perforin, interferon (IFN)-γ,o rSTAT1 genes
(thuslackinginterferon-mediatedpathways)inmiceresulted
in increased incidence and growth of spontaneous and
chemically-induced tumors [2–5]. Further evidence that the
adaptive immune system is involved in immune surveillance
of tumors was provided by experiments using RAG-2-
deﬁcient mutant mice [6]. The RAG genes encode DNA
repair enzymes which are essential for B-cell receptor (i.e.,
antibody) and T-cell receptor (TCR) rearrangement. Mice
with homozygous deletion of the RAG-2 alleles completely
lack NKT, T, and B cells and have an increased incidence
and growth of spontaneous tumors and chemically induced
cancer lesions [5]. In humans these ﬁndings are reﬂected
by the fact that immunocompromised patients, in particular
transplant recipients and patients suﬀering from acquired
immunodeﬁciency syndrome (AIDS), are more susceptible
to certain types of neoplasms [7, 8].
Although the theory of immune surveillance will remain
a matter of debate, it is meanwhile accepted that T cells
play a crucial role in controlling the development of
neoplastic lesions in vivo. T cells are activated via their T-
cell receptor, which binds to antigen peptides presented on
major histocompatibility complex class molecules (MHCs).
Following the recognition of peptides presented by MHC
classImolecules,activatedCD8+ cytotoxicTcells(CTLs)can
eﬃciently destroy target cells using death cell ligands such
as TRAIL (TNF-related apoptosis-inducing ligand) or by
executionoftheperforin/granzymepathway[9,10].Another
fraction of T cells, the CD4+ T cells, recognizing peptides2 Journal of Biomedicine and Biotechnology
presented by MHC class II molecules, play also an important
role in adaptive anticancer immunity [11]. CD4+ Tc e l l s
can improve the capacity of dendritic cells (DCs) to induce
CTLs by crosslinking the costimulatory molecule CD40 on
DCs with the CD40 ligand on activated CD4+ T cells [12].
Furthermore, by secreting cytokines such as interleukin-2
(IL-2), activated CD4+ T cells support the clonal expansion
of activated CTLs [13]. Besides this, activated CD4+ T
cells can signiﬁcantly boost cellular components of the
innate immunity, such as macrophages and NK cells by
enhanced IFN-γ secretion [14]. Concomitantly, increased
IFN-γ levels improve the recognition capacity of T cells
through induction of higher expression levels of MHC class
I molecules on the target cells [14, 15].
Despite ongoing surveillance by T cells and other
components of the immune system, tumors develop even
in presence of an intact immune system and become
eventuallyclinicallydetectable.Schreiberandcolleagueshave
put forward the hypothesis of cancer immunoediting to
explain this discrepancy [16]. According to their theory,
cancer development can be divided in three phases. In the
ﬁrst phase, immune surveillance is intact and cells of the
innate and adaptive immune system destroy neoplastic cells.
During the second phase a long-winded ongoing campaign
between the immune system and cancer cells establishes
a dynamic equilibrium. The third phase is characterized
by genetic and epigenetic instability of tumor cells which
eventually give rise to variants escaping from immune
surveillance (for reviewing see [16, 17]) and develop to
clinical apparent tumors. Due to the constant selective
pressure by the immune system, these variants display a
multitude of evasion mechanisms from immune recognition
and destruction. In the following paragraphs, we will focus
in particular on evasion strategies which outmanoeuvre the
immune recognition by T cells. Only a better understanding
of the manifold interactions between tumors and T cells
will help to improve current T-cell-based immunotherapy
strategies.
2. Central Tolerance and Peripheral
Tolerance MechanismsRestrict
Tumor-SpeciﬁcT-CellResponses
Tcellsurveillanceofneoplasticdevelopmentandgrowthpri-
marilydependsonrecognitionofprocessedso-calledtumor-
associated-antigen-(TAA-) derived peptides presented by
MHC class I molecules on the surface of tumor cells. Con-
ceptually, there are three diﬀerent types of TAAs: the ﬁrst
group are “neoantigens” which originate from transforming
viruses or are due to mutations or chromosomal aberrations
in the tumor cells and to which the host is not tolerant,
and secondly, “self-antigens” which are mainly proliferation
and diﬀerentiation markers overexpressed in tumors or
normal embryonic antigens aberrantly expressed in the
course of epigenetic changes and cellular dediﬀerentiation of
the tumor cells. Finally, the third group are “modiﬁed self-
antigens” representing self-antigens having diﬀerent tumor-
speciﬁc posttranslational modiﬁcations due to metabolic
disturbances (for reviewing see [18]). Most TAAs of solid
tumors correspond to self-antigens and modiﬁed self-
antigens which are re-expressed or overexpressed in tumors
and are barely detected in normal tissues. However, T
c e l l sw i t hh i g ha ﬃnity receptors for MHC/self-peptides are
eliminated during development in the thymus to establish
central tolerance. Therefore, the repertoire of T cells speciﬁc
for self-peptides in the periphery is restricted to those T
cells displaying a low aﬃnity T-cell receptor. Furthermore,
under normal circumstances T cells reactive against self-
peptides are in an ignorant state called peripheral tolerance
and need to be activated by professional antigen-presenting
cells (APCs), usually DCs, in a process termed cross-
priming, before they can exert their eﬀector functions
[19]. Brieﬂy, immunogenic responses of T cells require
that DCs must encounter antigens that are associated with
evolutionary conserved “pathogenic-associated molecular
patterns” (PAMPs) or in other words “danger signals”
derived from pathogenic microorganisms or viruses [20, 21].
After sensing such danger signals (i.e., LPS, CpG-rich DNA,
and viral RNA) via toll-like receptors (TLRs) or other sensor
molecules such as members of the retinoid inducible gene I
(RIG-I) family the DCs upregulate costimulatory molecules
such as CD80 and CD86 and now can fully activate CTLs in
concert with activated CD4+ T cells [12, 22–25]( Figure 1).
Despite the control mechanism of central tolerance, self-
reactive CD4+ T cells and CTLs exist in the periphery and
under certain conditions DCs can provide suﬃcient co-
stimulation to activate these cells as exempliﬁed in human
autoimmune diseases such as psoriasis and systemic lupus
erythematodes [26]. In particular, it has been shown that the
antimicrobial peptide LL37 from psoriasis patients activates
TLRs 7 and 9 when associated with self-nucleic acids [27].
Meanwhile, lines of evidence indicate that under certain
circumstances tumor cell death can also deliver danger
signals required for DC priming via TLRs. In fact, it has
been shown that release of several factors such as calreticulin
and high-mobility group box1 protein (HMGB1) from
dyingcancercellscancodeliverso-called“damage-associated
molecular pattern” (DAMP) signals to DCs which in turn
can break peripheral tolerance of T cells [28, 29]( Figure 1).
EspeciallyHMGB1whichassociateswithDNAfromnecrotic
cells has been shown to play a pivotal role during sepsis
and induction of TLRs [30]. Furthermore, the eﬀects of
some anticancer drugs, in particular anthracyclines and
platinum-based drugs and also radiotherapy, suggest an
immunogenic cancer cell death via calreticulin exposure and
HMGB1 release [31]. Anthracycline-based chemotherapy
limits tumor growth in wild-type mice, whereas mice with
homozygous deletion of TLR4 or its downstream eﬀector
molecule MYD88 (myeloid diﬀerentiation primary response
protein 88) failed to eﬃciently respond to chemother-
apy. In addition, it has been reported that colon cancer
patients having a loss of function allele of TLR4 exhibited
a reduced progression-free survival compared to patients
carrying the normal TLR4 allele after treatment with oxali-
platin (OXP) [28]. DCs which have not been primed by
PAMP or DAMP danger signals can also display self-anti-
gens in association with MHC molecules, but unlike in theJournal of Biomedicine and Biotechnology 3
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Figure 1: T-cell conversion from anergic to an activated status upon immunogenic cell death of tumor cells. The activation of tumor-
speciﬁc T cells is dependent on DCs, which endocytose tumor cell debris and apoptotic vesicles. After intracellular processing the DCs
present peptides derived from tumor-associated-antigens in complex with MHC class I molecules to T cells. Without the stimulation by
danger-associated molecular patterns (DAMPs), DCs remain immature in a hostile immunosuppressive milieu and anergize CD4+ Tc e l l s
and cytotoxic T cells (CTLs) resulting in peripheral tolerance. The release of inﬂammatory factors and the appearance of DAMPs lead to
activation of DCs (inﬂammatory DCs) which subsequently upregulate costimulatory molecules of the B7 family. Inﬂammatory DCs are able
to activate na¨ ıve CTLs through MHC I tumor peptide/TCR and B7/CD28 crosslinking. Furthermore, inﬂammatory DCs can activate na¨ ıve
CD4+ T cells after MHC class II tumor peptide/TCR and B7/CD28 crosslinking. Activated CD4+ T cells in turn support clonal expansion
and activity of CTLs by CD40/CD40L interaction and release of inﬂammatory cytokines such as IL-2.
primed state, they cannot provide suﬃcient costimulation
for T-cell activation. Consequently, T cells recognizing
MHC/peptide complexes on the surface of nonactivated
DCs become anergic and eventually undergo apoptosis in
a process termed cross-tolerance [32]( Figure 1). Cross-
tolerance is a major hurdle for the generation of potent CTL
immune responses against self-antigens as seen in various
tumors where immature DCs mostly lacking costimulatory
receptors are not able to elicit T-cell responses [33–36].
In summary, evidence is accumulating that immunogenic
cell death of tumor cells provides tumor antigens and
concomitant danger signals to DCs which are now able to
activate tumor-speciﬁc T cells which can appear as so-
called tumor-inﬁltrating lymphocytes (TILs) at the tumor
site. So far, TILs, which were proven to speciﬁcally react
against tumor cells or which were associated with a better
clinical outcome, were reported for advanced ovarian cancer
[37], breast cancer [38, 39], melanoma [40], and colorectal
cancer [41]. Yet, the appearance of TILs in patients per se
did not predict an eﬃc i e n ti m m u n er e s p o n s eo ri m p r o v e d
clinical outcome against the tumor since various further
mechanisms, commonly deﬁned as “tumor escape mecha-
nisms,” can impair the eﬀector function of tumor-reactive
T cells.4 Journal of Biomedicine and Biotechnology
3. Defective Recognition of Tumors by
Activated T Cells
One of the best studied evasion mechanisms of tumor
cells to escape recognition by CTLs are abnormalities in
the antigen presentation machinery (APM). This includes
downregulation or complete loss of MHC class I molecules
as observed in head and neck squamous carcinoma [42],
human esophageal squamous carcinoma [43], lung cancer
[44], and prostate carcinoma [45]. Downregulation of MHC
class I molecules can be caused by point mutations or by
large deletions correlating with loss of heterozygosity (LOH)
on chromosome 6p21 [46, 47]. Another reason for defective
MHC class I surface expression as detected in colorectal
tumors and melanoma is due to mutated β2-microglobulin
(β2m) which severely impairs the transport of MHC class I
molecules to the cell surface [48, 49]. Moreover, disturbed
transcriptional regulation, such as decreased levels or loss
of locus-speciﬁc transcription factors as well as epigenetic
alterations like DNA hypermethylation can contribute to the
decrease of MHC class I expression [43, 50, 51].
Assembly and transport of HLA class I molecules to the
cell membrane crucially depends on the APM. The APM
includes the proteasome subunits of low-molecular mass
polypeptides 2 and 7 (LMP2 and LMP7), transporter associ-
ated with antigen processing 1 and 2 (TAP1 and TAP2), and
several chaperons such as tapsin (for reviewing see [52]). In
melanoma and renal cancer, cell lines promotor methylation
has been demonstrated as a mechanism to inhibit or impair
expression of tapsin, TAP2, and TAP1 that ﬁnally leads to a
decrease or loss of MHC class I surface expression [53, 54].
IFN-γ plays a major role in the regulation of the APM.
Particularly,TAP1andLMP2genesarecontrolledbyashared
bidirectional IFN-γ-dependent promoter. In the presence of
IFN-γ, the transcription factor interferon regulatory factor-
1 (IRF-1) binds the interferon regulatory element (IRF-
E) within the TAP1/LMP2 promoter and enhances the
expression of TAP1 and LMP2 [55]. Epigenetic silencing
of IRF-1 transactivation results in IFN-γ unresponsiveness
and subsequently in lower expression levels of MHC class I
molecules [56]. Further defects within the IFN-γ signaling
pathway such as deletion or mutations in Janus kinases 1
and 2 (Jak1 and JAK2) genes, downstream of IFN-γ receptor
and upstream of STAT1 have been described in several IFN-
γ-resistant melanoma cell-lines and uterine leiomyosarcoma
[57, 58]. Therefore, in certain tumors lack of IFN-γ sensitiv-
ity supports immune evasion from CTL recognition.
Besides the impaired MHC-class-I-dependent recogni-
tion, tumor cells can avoid confrontation with T cells by
inhibiting extravasation of lymphocytes to the tumor site.
Defects in adhesion of molecule expression on blood vessels
have been described in human breast cancer [59], melanoma
[60],andhumansquamouscellcarcinoma[61].Noteworthy,
it was shown that decreased expression levels of addressins
E-Selectin, P-Selectin, and intercellular adhesion molecule-
1 (ICAM-1) in blood vessels of melanoma resulted in
impaired T-cell extravasation at the tumor site when com-
pared to accumulation of T cells in adjacent healthy tissue
[62].
4.ResistancetoT-Cell-Mediated
Killing Mechanism
In the last years evidence accumulated that altered or defec-
tiveapoptoticpathwaysmightcontributetoimmuneevasion
of tumors. There are two distinct eﬀector mechanisms, how
T cells can eliminate target cells such as virus-infected cells
or malignant cells. Generally, they induce apoptosis by the
calcium-dependent “perforin/granzyme pathway” or by the
calcium-independent “death receptor pathway”. During the
last years, in vivo and in vitro studies have demonstrated that
tumor cells can resist killing by CTLs through interference
with the perforin/granzyme pathway, caused by the expres-
sion of the granzyme B inhibiting serine protease inhibitor
PI-9/SPI-6. In particular melanoma, cervical carcinoma, and
breast carcinoma were demonstrated to express PI9/SPI-6
[63]. A recent study revealed a poorer clinical outcome of
vaccinated melanoma patients when the tumors expressed
PI9/SPI-6 [64].
Death receptors are members of the tumor necrosis fac-
tor (TNF) receptor superfamily and are characterized by an
intracellular death domain (DD). The crosslinking of death
r e c e p t o r ss u c ha sC D 9 5( F a s ;A p o - 1 )a n dT R A I Lr e c e p t o r
1 and 2 on tumor cells with their natural ligands CD95L
andTRAILinduceformationofthedeath-inducingsignaling
complex (DISC). Within the DISC, procaspase-8 is recruited
by the DD-associated adaptor protein Fas-associated death
domain protein (FADD/MORT-1) and activated by autocat-
alytic cleavage. This event initiates downstream apoptotic
processes causing mitochondrial cytochrome C eﬄux and
subsequent activation of eﬀector caspases-3, -6, and -7 [65].
The induction of apoptosis through death receptor signaling
canbeblockedintumorcellsatseveralsteps.Forexample,in
melanoma cells high levels of antiapoptotic regulator FLICE
inhibitory protein (c-FLIP) have been shown to correlate
with increased resistance to TRAIL-mediated apoptosis [66].
Due to its structural homology to procaspase-8, but lacking
a catalytic site, c-FLIP binds to DISC and inhibits cleavage
of procaspase-8 [67]. C-FLIP has been detected in diﬀerent
types of cancer and cancer cell lines [68–71]. In particular
its increased expression in colorectal cancer predicts a
poorer clinical outcome [72]. Moreover, tumor cells can
obtain further apoptotic resistance by downregulation or
inactivation of death receptors. Loss of CD95/FAS can occur
at the transcriptional level which seems to be aﬀected by
oncogenicras [73]orlossoffunctionalp53[74].Adecreased
expression of CD95/FAS also has been found in colon cancer
[75]. Noteworthy, expression levels of CD95/FAS in colon
cancer cell lines can be improved by TNF-α and IFN-γ [75].
Besides transcriptional downregulation, a variety of tumor-
associated mutations and deletions can lead to a loss of
function of CD95/FAS and TRAIL receptors. For example,
lack of cytoplasmic signaling domains of CD95/FAS, TRAIL-
R1, and -R2 was detected in multiple myeloma [76], adult
T-cell leukemia [77], gastric cancer [78], and breast cancer
[79].
Another mechanism by which tumors gain resistance to
apoptosis is the expression of transmembrane and soluble
decoy receptors with a truncated nonfunctional or a missingJournal of Biomedicine and Biotechnology 5
death domain, respectively. Interactions of ligands with their
respective decoy receptors have been shown to competitively
inhibit death receptor signaling. So far, diﬀerent decoy
receptors for CTL’s death ligands CD95L and TRAIL have
been characterized: soluble CD95/FAS (sCD95) in various
malignancies [80–82], decoy receptor 3 (DcR3) in lung
cancer [83], colon cancer [83], as well as glioblastoma [84],
and TRAIL-R3 (DcR-1) in primary gastrointestinal tract
(GIT) cancers [85], TRAIL-R4 (DcR-2) in colon cancer [86],
and TRAIL-R5 (Osteoprotegerin; OPG) in breast [87]a n d
prostate cancer [88].
5.InductionofAnergy inActivatedTCells
Inhibitory coreceptors, including “cytotoxic T lymphocyte
antigen-4” (CTLA-4) and “programmed death-1” (PD1),
play a major role in maintaining peripheral T-cell tolerance.
These inhibitory coreceptors are upregulated during T-cell
activation and interact with molecules of the B7 family
that are found on DCs but are also expressed in many
tumortissues[89].CTLA-4competeswiththecostimulatory
receptor CD28 in binding to CD80 (B7.1) and CD86 (B7.2)
moleculesandactivatesproteinphosphatase2A(PP2A)[90].
PPA2dephosphorylatesAktkinaseandthereforeantagonizes
the TCR/CD28 signaling pathway resulting in decreased IL-
2 production, impaired TCR signalling, and cell cycle arrest
[91, 92]. The inhibitory T-cell receptor PD1 which is upreg-
ulated by IFN-γ [93] interacts with the B7 family member
B7-homolog 1 (B7-H1) which is found in many tumor
types [94–98]. Increased B7-H1 levels correlate with a poor
outcome in ovarian cancer, esophageal cancer, and urothe-
lial cancer [94–96]. Mechanistically PD1/B7-H1 interaction
leads to recruitment of SH2-containing protein tyrosine
phosphatases-1 and -2 (SHP-1, -2) at the immunoreceptor
tyrosine-based switch motif of PD1 which ultimately results
in downstream signals inhibiting phosphoinositide 3 kinase
(PI3K) activity and disruption of TCR/CD28 signaling [99].
Furthermore, an induction of IL-10 was observed which
might inﬂuence suppressive activity of Tregs (discussed in
Section 7)[ 89]. A soluble form of B7-H1 was detected in
aggressive renal cell carcinoma which could further promote
immunosuppression [100].
Furthermore, anergy in T cells can be induced by high
levels of intratumoral TGF-β and of the arachidonic acid
derivative prostaglandin E2 (PGE2). TGF-β controls T-cell
homeostasis by inhibiting T-cell activation, proliferation,
and diﬀerentiation [101, 102]. Numerous in vivo and in vitro
studies demonstrated that expression of TGF-β at the tumor
site correlates with poor prognosis in many human cancer
types such as colorectal cancer, esophageal adenocarcinoma,
glioblastoma, breast cancer, and lung cancer [103–107].
However, the molecular mechanisms which eventually lead
to TGF-β-mediated T-cell inhibition are still not well
characterized. It is hypothesized that the TGF-β-induced
mRNA downregulation of TCR components and signaling
molecules like IL2-inducible T-cell kinase (ITK), ZAP70,
and CD3-zeta chain results in an insuﬃcient T-cell signal
transduction [108]. Furthermore, TGF-β is also known for
blocking the cytotoxic reaction of CTLs by transcriptional
repression of genes encoding the cytotoxic mediators per-
forin, granzyme A and B, FasL, and INF-γ [109]. More
recently, accumulating data suggests that under certain
circumstances TGF-β also impairs the function of tumor-
reactive CD4+ T cells by inducing them to become FoxP3-
positive regulatory T cells (“Tregs”, discussed in Section 7)
[110].
The inducible isoform of the cyclooxygenase enzyme
C O X 2i so v e r e x p r e s s e di ns e v e r a lt u m o rt y p e sa n dp r o d u c e s
PGE2 which aﬀects various processes relevant to tumorige-
nesis such as apoptosis, angiogenesis, and migration [111].
It is proposed that PGE2 shifts the immune system to
a Th2-type response. Supporting evidence came from the
observation that breast cancer patients showing increased
intratumoral COX2/PGE2 expression had impaired DC and
T-cell function, reduced Th1-type, and increased Th2-type
cytokine levels in the serum [112]. In addition, it has
also been proposed that PGE2 augments the induction of
FoxP3 in CD4+ T cells [113]. In particular, mice with
homozygous deletion of the PGE2 receptor P4 gene showed
signiﬁcantly reduced intratumoral levels of FoxP3+ Tregs,
increased serum level of Th1-type cytokines, and an increase
in IFN-γ-dependent antitumor reactivity of T cells [114].
Another immune evasion mechanism of tumors is based
on protein-glycan interactions involving galectins. Galectins,
deﬁned as glycan-recognizing proteins with an aﬃnity
for β-galactosides, aﬀect many cellular functions including
adhesion, migration, chemotaxis, proliferation, apoptosis,
anddiﬀerentiation[115–117].Duringthelastyears,galectins
have been recognized as natural immunosuppressive pro-
teins which also inhibit antitumor immune responses.
Their overexpression in tumors such as melanoma [118],
glioblastoma [119], prostate cancer [120], bladder cancer
[121], ovarian cancer [122], and breast cancer [123]o f t e n
correlates with tumor aggressiveness. Especially galectin-1
mightplayanimportantroleinimmuneevasionbyinducing
T-cell apoptosis [124, 125]. So far little is known about how
galectinsimpairT-cellfunctions.Yet,someevidencesuggests
that galectin-1 interferes with the correct assembly of the T-
cell receptor complex in lipid rafts [126].
6. Tumor Cell“Counter Attack”
In an immunocompetent organism, T-cell activation by
pathogens leads to a clonal expansion of antigen-speciﬁc
T cells. Once they have accomplished their mission, T-cell
expansion bearing the inherent danger of autodestruction is
terminated by T-cell activation-induced cell death (AICD)
resulting in clonal contraction of antigen-speciﬁc T cells
[127]. The CD95/FAS death receptor, which is upregulated
in activated T cells, is playing a key role in AICD. It is
well known that upon TCR engagement in the absence of
costimulation, T cells express high amounts of Fas ligand
(FasL), which is assumed to induce apoptosis of these T
cells (“suicide”) and between T cells (“fratricide”). Yet,
some tumors such as melanoma [128], lung cancer [129],
pancreatic cancer [130], and breast cancer [131] express FAS
ligand (FasL), which might accelerate AICD and therefore6 Journal of Biomedicine and Biotechnology
could contribute to tumor immune evasion. First evidence
that FasL can confer resistance to T-cell-mediated tumor
rejection was demonstrated by delayed growth of FasL-
positive melanoma cells in lpr-positive mice (lpr,l y m -
phoproliferation gene, encoding mutated CD95/FAS with
loss of function) when compared to congenic controls,
supporting the concept that tumor cells can eliminate
eﬀector T cells by FasL counter attack [128]. However,
despite accumulating data in support of FasL counter
attack, many conﬂicting studies have reported that FasL
can also induce proinﬂammatory and antitumoral eﬀects in
vivo. In particular, tumor xenografts genetically modiﬁed
to express membrane-bound FasL showed an accelerated
rejection which was accompanied by neutrophil inﬁltration
[132–134]. In contrast, a more recent study revealed that
antisense-mediated downregulation of FasL in colon cancer
cells reduced tumor growth in syngeneic and immune
competent mice [135]. It remained to be clariﬁed whether
other factors such as cytokines, tumor microenvironment,
or technical peculiarities account for the diﬀerent outcomes.
The situation becomes far more complex by a recent report
describing the appearance of so called microvesicles con-
taining FasL which were found to be released by melanoma
cells [136]. These microvesicles are endosome-derived small
particles of 50 to 100nm in size and are secreted through
exocytosis pathways [137]. These microvesicles were able
to induce cell death in lymphoid cells and furthermore
might cause systemic immunosuppressive eﬀects in patients
[136]. In particular, it is assumed that besides the eﬀects of
death receptor ligands the microvesicles can carry various
immunomodulatory factors that exert immunosuppressive
eﬀects on lymphocytes in draining lymph nodes but also
modulate myeloid-derived cells to become myeloid-derived
suppressor cells (MDSC) [137] (which are further discussed
in Section 7).
In addition to FasL-mediated apoptosis induction in
antitumor eﬀector cells, a recent report also described
expression of TRAIL in hepatocellular carcinoma which
induced cell death of Jurkat leukemia T cells [138].
Another mechanism that may contribute to tumor
evasion from tumor-speciﬁc T cells is based on the expres-
sion of the enzyme indoleamine 2,3-dioxygenase (IDO).
This heme-containing enzyme degrades the essential amino
acid tryptophan and catalyzes the initial and rate-limiting
step of the kynurenine pathway leading to nicotinamide
dinucleotide (NAD) biosynthesis. Initially, IDO was thought
to represent a defence mechanism against bacteria, but it
soon became evident that IDO plays a physiological role in
theestablishmentofanimmuneprivilegeatthefetoplacental
border. IDO expression at this site is proposed to block T-cell
attack and therefore protects the embryo [139]. This eﬀect
was conﬁrmed by in vitro studies showing that tryptophan
depletion led to cell cycle arrest in T cells [140]. So far IDO
expression was found in several primary tumors such as
gastric cancer, colon cancer, and renal cell carcinoma as well
as in derived cell lines [141]. Interestingly, some of the tumor
cell lines expressed IDO only after IFN-γ treatment and
the activity of IDO could be blocked by administration of
the speciﬁc inhibitor levo-1-methyl-trypthopan [141]. Thus,
in certain tumors pharmacological blockade of IDO may
impair the development of an immune privileged tumor site
and may improve immunotherapy.
7. ImmunosuppressiveRoles of FoxP3+
Regulatory TCellsandofMyeloid-Derived
SuppressorCells(MDSCs)
The existence of peripheral T cells exerting a suppressor
function has been a matter of debate for many years.
Nowadays it is widely accepted that a distinct population
of CD4+ cells constitutively expressing the surface markers
CD25 (the alpha-chain of the IL-2 receptor) and accounting
for approximately 5–10% of all peripheral T cells can
suppress responses of tumor-speciﬁc CD4+ T cells and
CTLs [142]. Moreover, these cells, designated Tregs, are
characterized by the expression of the transcription factor
forkhead box P3 (FoxP3), CTLA-4, glucocorticoid-induced
TNF receptor (GITR), and by their ability to suppress the
activation of other T-cell subpopulations [110, 143, 144].
In humans, high numbers of CD4+ CD25+ Tregs were
found in head and neck cancer [145], lung cancer [146, 147],
pancreatic cancer [148], breast cancer [149], liver cancer
[150], ovary cancer [151], and gastrointestinal cancer [152]
either in the circulation or in the tumor itself. The appear-
ance of Tregs at the tumor sites often correlates with poor
prognosis of cancer patients [148, 151, 153, 154]. So far, it is
notclariﬁedwhyandhowTregsaccumulateatthetumorsite.
As a mechanism of Treg recruitment, it has been proposed
that tumor cells or tumor-inﬁltrating macrophages secrete
the chemokine CCL22 which chemoattracts CD4+CD25+
Tregs [151, 155]. On the other hand, it is also likely
that the immunosuppressive milieu of the tumor, that is,
high concentrations of TGF-β, induces tumor inﬁltrating
CD4+ T cells to become FoxP3+ Tregs [110]. Tregs, either
regular Tregs or induced Tregs prevent antitumoral immune
responses by inhibiting tumor-speciﬁc CD4+ cells and CTLs.
Anotherrecentlydescribedimmunosuppressivecellpop-
ulation in tumors are the MDSCs [156, 157]. These cells
are generated in response to a variety of tumor-derived
cytokines and appear as heterogenous populations repre-
senting myeloid cells at diﬀerent stages of diﬀerentiation.
In advanced cancer stages peripheral blood MDSCs were
found to inhibit IFN-γ production by autologous CD8+
T cells stimulated with peptide-pulsed DCs [156, 158]. It
is hypothesized that the appearance of MDSCs in tumors
and in peripheral blood might be due to increased gran-
ulocyte macrophage colony-stimulating factor (GM-CSF)
levels produced by human tumor cells [159–162] and that
the immunosuppressive phenotype is induced by tumor-
derived microvesicles [137]. Meanwhile, some evidence is
accumulating that MDSCs might inhibit T cells by the
production of amino acid metabolizing enzymes such as
arginase, nitric oxide synthetase and the production of
reactive oxygen species (ROS) [157, 158, 163]. Especially,
the chemical modiﬁcation of T-cell receptors by reactive
nitrogenous species was demonstrated to impair binding to
the cognate MHC/peptide complex [163].Journal of Biomedicine and Biotechnology 7
8. ImmunotherapeuticalApproaches to
InduceAntitumor T-Cell Responses
An u m b e ro fd i ﬀerent immunotherapeutic approaches focus
on the generation of an eﬀective T-cell-mediated antitumor
response in patients (Table 1). Exploiting T cells as a target
tool for cancer treatment seems to be advantageous as T cells
have an exact speciﬁcity for their target, can home into
antigen-expressing tumor sites and can generate a long-
lasting immune response against reoccurrence of the disease.
However, so far none of the various T-cell-dependent ap-
proaches has been established as a routine clinical treatment
strategy for cancer as, for example, monoclonal antibody-
based pharmaceuticals have been in the last years. The failure
of various T-cell-based immunotherapeutic approaches in
clinical studies is related in many aspects to escape mech-
anisms of tumors from T cell surveillance and the im-
munosuppressive eﬀects mediated by tumors described in
the preceding chapters (summarized in Figure 2). While in
this section we will describe immunotherapeutic approaches
using DCs and TILs, in the following sections we will give
an overview on new strategies to enhance T-cell-mediated
anti-tumor response.
Strategies based on vaccination with tumor cell lysates,
TAAs, or tumor peptides can elicit antitumoral responses
through priming of DCs and subsequent activation of
tumor-speciﬁc T cells [164]. However, many clinical trials
weredisappointing intermsoftumorregressionorincreased
survival rates [164]. Potential reason for failure of this
vaccination strategy can be alterations in number as well as
functionaldefectsinDCswhichhasbeenobservedinanum-
ber of patients [33, 35]. In addition, lack of immunological
response seemedto bemore severein patients bearing a large
tumor burden and is likely caused by immunosuppressive
factors released by the tumor, Tregs [101]a n dM D S C s[ 165].
It is assumed that induction of T-cell tolerance by immature
or dysfunctional DCs is mostly responsible for the observed
unresponsiveness of T cells [164]. Therefore, new vaccine
strategies concentrate on the targeting of certain DC subsets
and codelivery of PAMP or DAMP signals to DCs to improve
the T-cell priming capacities. In particular, activators of
TLRs, for instance the cytosine-phosphate-guanosine (CpG)
dinucleotide CpG 7909, which induces TLR9 activation,
cameintothefocusoftumorimmunotherapy.Intradermally
injected CpG 7909 near the tumor site obviously provided
suﬃcient danger signals to plasmacytoid DCs which in turn
were able to elicit melanoma responsive CTLs in sentinel
lymph nodes of patients, whereas in patients treated with
saline no melanoma-reactive CTLs were detected [166]. The
chemical compound imiquimod, a potent TLR7 agonist, has
been approved for treatment of basal cell carcinoma [167]
and was shown to improve survival of glioblastoma patients
bearing tumors with mesenchymal gene expression proﬁle
and vaccinated with ex vivo tumor cell lysate pulsed DCs
[168].
Another strategy to enhance vaccination-induced T-
cell activation is the ex vivo modulation of autologous or
allogeneic DCs. This is often accomplished by incubation
with factors like type-1 and type-2 interferons, TLR ligands
or GM-CSF, which all enhance the antigen-presenting and
T-cell activating capacities of DCs [164]. As an encour-
aging result of these eﬀorts, Sipuleucel-T, a dendritic-cell-
based vaccine recently approved by the FDA and based
on peripheral blood cells ex vivo stimulated with a fusion
protein of prostatic acid phosphatase and GM-CSF was
shown to improve survival of prostate carcinoma patients
in a phase III trial [169]. Furthermore, depletion of Tregs
prior to vaccination of ex vivo-modulated DCs can be used
to improve immune responses. In particular, Denileukin
diftitox, an IL-2 peptide fused to diphtheria toxin which is
approved for treatment of cutaneous T-cell lymphoma [170]
enhanced T-cell activation of patients when applied before
vaccination with DCs ex vivo transduced with a fowlpox
vector encoding the TAA carcinoembryonic antigen [171].
Furthermore, the direct transfer of tumor-speciﬁc either
allogeneic or ex vivo expanded patient-derived autologous
T cells emerged as a promising approach for cancer
immunotherapy (adoptive cell therapy, ACT). The rationale
behind this strategy is to circumvent or break tolerance
against the tumor by the transferred T cells. Direct clinical
evidence has accumulated that adoptively transferred T cells
can delay or even prevent tumor relapse after initial standard
treatment [172]. Yet, in this ﬁrst clinical trial the response
ratewasonlytransient,andtransferredtumor-speciﬁcTcells
vanished rapidly [173]. Recently, improvements of ex vivo
cultivationconditionsandmoreimportantlymphodepletion
prior to infusion of T cells led to remarkable cancer regres-
sion [174–176]. One probable explanation for the eﬃciency
of ACT after lymphodepletion might be the removal of
immunosuppressive Tregs.
9. ImprovingAntitumoral Responses by
BlockingSelf-RestrictingInhibitory
CircuitsofTCells
To further improve the outcome of immunotherapy
immune-restrictive signals to T cells can be either blocked or
eliminated. In particular, blocking antibodies can be utilized
for switching oﬀ self-restricting inhibitory circuits of T cells
directly at the site of the tumor, resulting in enhanced antitu-
morimmuneresponses.Promisingcandidatesareantibodies
inhibiting CTLA-4 [177] which blocks the intrinsic T-cell
regulatory pathway or anti-B7-H1 antibodies which block
extrinsicT-cellinhibitorypathwaysdrivenbyligandsonDCs
and tumor cells, respectively [98, 178]. In preclinical studies,
blockade of B7-H1 has resulted in enhanced antitumoral
immune responses [98, 178]. Recently, a blocking anti-
PD1 antibody (MDX-1106), the receptor for B7-H1 on T
cells, has been evaluated in a clinical phase I study. So
far, MDX-1106 was well tolerated in most patients bearing
diﬀerent solid tumor types. A small proportion of patients
showed complete and partial responses to treatment whereas
one case was associated with development of inﬂamma-
tory colitis [179]. So far no clinical studies using PD-1
blockade during immunotherapeutic approaches have been
reported. In preclinical mouse models CTLA-4 blockade-
based immunotherapy enhances the T-cell-mediated killing8 Journal of Biomedicine and Biotechnology
Table 1: Selected approaches to tumor immunotherapy.
Approach Target Agent Immune modulation
of host
Phase of
experimentation Main ﬁndings
Vaccination Glioma Tumor-cell lysate pulsed DCs —
Phase I clinical trial
completed
(NCT00576537)
T-cell responses,
detection of
inﬁltrating T cells in
recurrent glioma
associated with
prolonged survival
[210]
Vaccination
Adenocarcinoma
of the prostate
expressing
“prostatic acid
phosphatase”
(PAP)
DCs ex vivo primed with
PAP-GM-CSF fusion protein
(Sipuleucel T, FDA-approved
for treatment of
hormone-refractory prostate
cancer)
—
Phase III clinical trial
completed
(NCT00065442)
Increased overall
survival, but no
increase in
progression-free
survival of patients
[169]
Vaccination and
chemotherapy
(Doxetacel)
Breast cancer
with expression
of MUC-1, CEA
Recombinant Vaccinia and
Fowlpox virus (PANVAC)
encoding MUC-1 and CEA
GM-CSF treatment
during vaccinations
Phase II clinical trial
ongoing
(NCT00179309)
Induction of T-cell
speciﬁc immune
responses [211]
Vaccination
Adenocarcinoma
of the prostate
expressing “TCRγ
Alternative
Reading frame
Protein”
Vaccination with TARP
peptides
Use of Montanide
ISA-51 VG as
adjuvant and
concomitant
GM-CSF treatment
Preclinical study and
phase-I clinical trial
ongoing
(NCT00908258)
Preclinical study
demonstrated
induction of
T-cell-speciﬁc
immune responses
[212]
Vaccination Melanoma MART-1-, gp100-, tyrosinase-
peptides
Subcutaneous
injection of IFN-α2b
and/or GM-CSF
Phase II clinical trial
completed (ECOG
E1696)
Neither IFN-α2b nor
GM-CSF improved
immune responses,
35% of patients
developed T-cell
responses associated
with prolonged
median overall
survival [213]
Vaccination Melanoma MAGE-3.A1 peptide and/or
NA17.A2 peptide
peritumoral injection
of IL-2, IFN-α and
GM-CSF, and topical
application of
imiquimod
Phase I/II clinical trial
ongoing
(NCT01191034)
—
Vaccination CEA expressing
cancers
Ex vivo activation of DCs
using recombinant Fowlpox
virus encoding CEA
Denileukin
diftitox-mediated
depletion of Tregs
Phase I clinical trial
ongoing
(NCT00128622)
Increased T-cell
responses to
CEA-positive target
cells [171]
Vaccination
Melanoma Tyrosinase/gp100/MART-1
Peptides
Use of Montanide
ISA-51 VG as
adjuvant, treatment
with anti-CTLA4
antibody (MDX-010)
Phase I/II clinical trial
ongoing
(NCT00028431)
T-cell reactivity
against gp100 and
MART-1. CTLA-4
antibody dose-related
adverse autoimmune
eﬀects in skin and
gastrointestinal tract
[214]
Melanoma gp100 peptides
Vaccination using
incomplete Freund’s
adjuvant, treatment
with anti-CTLA4
antibody
(Ipilimumab)
Phase II clinical trial
completed
(NCT00094653)
Improved overall
survival when
applying Ipilimumab
irrespective of gp100
vaccination, adverse
immunological site
eﬀects [185]Journal of Biomedicine and Biotechnology 9
Table 1: Continued.
Approach Target Agent Immune modulation
of host
Phase of
experimentation Main ﬁndings
Vaccination Glioma Tumor cell lysate pulsed
dendritic cells
TLR agonist
Imiquimod
Phase II clinical trial
ongoing
(NCT01204684)
Improved survival of
as u b s e to fg l i o m a
patients [168]
Vaccination Leukemia Autologous leukemia cells
Autologous skin
ﬁbroblasts transduced
with recombinant
adenoviral vectors
encoding CD40L and
IL-2
Phase I/II clinical trial
ongoing
(NCT00058799)
Observed immune
responses including
antibodies against
leukemic blasts,
prolonged survival
time of patients [215]
TLR agonist
monotherapy
TLR 9 in
Melanoma CpG 7909 —
Phase II clinical trial
completed
(NCT00070642)
Increased frequencies
of T cells reactive
against target cells
expressing
melanoma-
associated-antigens in
sentinel lymph nodes
[166]
TLR agonist
monotherapy
TLR7 in basal cell
carcinoma Imiquimod —
Phase II clinical trial
completed
(NCT00189241)
FDA approved for
treatment of
superﬁcial basal cell
carcinoma [167]
Immunotoxin
monotherapy
Renal cell
carcinoma
Denileukin diftitox
(IL-2-diphteria toxin fusion
protein)
Complementary IL-2
treatment
Phase I clinical trial
completed
(NCT00278369)
Partial depletion of
Tregs, no increase in
antitumor response
rates when compared
to controls [216]
TGFβ antisense
(AS)
oligonucleotide
monotherapy
TGFβ expression
in patients with
recurrent high
grade glioma
TGFβ AS (AP-12009,
Trabedersen)
Local depletion of
TGFβ
Phase IIb clinical trial
completed
(NCT00431561)
Well tolerated,
increased median
survival time of
patients [195]
Anti-TGFβ
antibody
monotherapy
TGFβ expression
in patients with
renal cell
carcinoma,
melanoma
Blocking anti-TGFβ antibody
(GC-1008)
Systemic depletion of
TGFβ
Phase I clinical trial
safety and eﬃcacy
study
(NCT00356460)
—
Anti-PD-1
antibody
monotherapy
Refractory or
relapsed
malignancies
(solid tumors)
Anti-PD-1 antibody
(MDX-1106)
Blocking extrinsic
self-regulatory
pathways of T cells
Phase I clinical trial
(NCT00441337)
Complete and partial
responses, induction
of inﬂammatory
colitis [179]
Anti-CD137/4-
1BB
monotherapy
Melanoma Anti-CD137/4-1BB antibody
(BMS-663513)
Systemic
co-stimulation of T
cells
Phase II clinical trial
completed
(NCT00612664)
[188]
—
Adoptive cell
therapy Melanoma Ex vivo expanded TILs
Chemotherapy-
mediated
lymphodepletion
prior infusion of
TILs, high dose IL-2
treatment
Phase II clinical trial
ongoing
(NCT00513604)
Objective clinical
responses, in some
cases durable
complete responses,
toxic side eﬀects after
chemotherapy and
high IL-2 doses
[174, 176]
Adoptive cell
therapy Melanoma
Ex vivo expanded TILs
enriched for CD8∗ Tc e l l s
genetically engineered to
express IL-12
Chemotherapy-
mediated
lymphodepletion
prior infusion of TILs
Phase I/II clinical trial
ongoing
(NCT01236573)
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Table 1: Continued.
Approach Target Agent Immune modulation
of host
Phase of
experimentation Main ﬁndings
Genetic
manipulation of
Tc e l l sf o r
immune therapy
Neuroblastoma
cells expressing
L1-CAM
(CD171)
Ex vivo generated
anti-CD171-CAR engineered
Tc e l l s
—
Phase I/II clinical trial
completed
(BB-IND#9149, FDA)
Weak tumor
responses and limited
persistence of
CD171-CAR [201]
Genetic
manipulation of
Tc e l l sf o r
immunotherapy
Non-Hodgkin
lymphoma and
mantle cell
lymphoma
Ex vivo generated
anti-CD20-CAR engineered
Tc e l l s
Low dose IL-2
treatment
Phase I/II clinical trial
completed
(NCT00012207)
No side eﬀects,
regression of tumors,
persistence of
modiﬁed T cells for 9
weeks [202]
Genetic
manipulation of
Tc e l l sf o r
immunotherapy
Metastatic
cancers that
express
NY-ESO-1
Ex vivo generated anti-NY
ESO-1 TCR-gene engineered
Tc e l l s
Chemotherapy-
mediated
lymphodepletion
prior infusion of
modiﬁed T cells.
Modiﬁed T cells are
further stimulated
using ALVAC–ESO-1
vaccine, G-CSF and
high dose IL-2
treatment
Phase II clinical trial
ongoing
(NCT00670748)
—
Genetic
manipulation of
Tc e l l sf o r
immunotherapy
B-cell
malignancies
with expression
of CD19
Ex vivo generated
anti-CD19-CAR engineered
Tc e l l s
Chemotherapy-
mediated
lymphodepletion
prior infusion of
TILs, high dose IL-2
treatment
Phase I/II clinical trial
ongoing
(NCT00924326)
Regression of B-cell
lymphoma and
elimination of B-cell
precursors in patients
[203]
Genetic
manipulation of
Tc e l l sf o r
immunotherapy
Metastatic
cancers
expressing Her2
Ex vivo generated
anti-Her2-CAR engineered
Tc e l l s
Chemotherapy-
mediated
lymphodepletion
prior infusion of
modiﬁed T cells, IL-2
treatment
Phase I/II clinical trial
completed
(NCT00924287)
—
ClinicalTrials.gov identiﬁer, Eastern Cooperative Oncology Group (ECOG) identiﬁer, and FDA-authorized pilot clinical study identiﬁer are given in brackets.
of tumor cells such as prostate [180]a n dc o l o nc a n c e r[ 181].
Also anti-CTLA-4 antibodies have entered the clinic and
have been used as monotherapy or in combination with
vaccination strategies targeting melanoma [182]. Although
clinical responses were observed in some patients with
metastatic melanoma or renal cell cancer in a phase I clinical
trial with humanized anti-CTLA-4 antibody (ipilimumab),
caution is advised since CTLA-4 blockade in some patients
caused immune-mediated site eﬀects such as hypophysitis,
enterocolitis, and nephritis [183–185]. Alternatively, ago-
nistic antibodies speciﬁc for costimulatory receptors can
be applied to improve T-cell responses to tumors. An
example is CD137 (4-1BB) antibodies which trigger via
their receptor the upregulation of antiapoptotic BclXL, Bﬂ-
1, and c-FLIP through the PI3K/Akt and NFκBp a t h w a y s
and therefore rendered reactive T cells more resistant to
AICD [186, 187]. Notably, a humanized monoclonal anti-
CD137/4-1BB antibody (BMS-663513) has entered a clinical
phase II trial as a second line monotherapy for previously
treated unresectable melanoma, but so far no combinations
with immunotherapeutic approaches have been reported
[188]. Other attempts focus on OX40 (CD134), a co-
receptor playing a central role in generating CD4+ and
CD8+ memory cells [189]. A preclinical study using OX40L
or an agonistic antibody during vaccination was shown to
augment protection against melanoma, breast and colon
carcinoma, and sarcoma in mice [190]. Currently, the role
of OX40-OX40L interaction in the induction, maintenance,
and function of Tregs came into focus of interest. Some lines
of evidence support the view that OX40-OX40L interaction
inhibit the induction of Tregs in the tumor, which might
further enhance immunotherapy of cancer [189].
10.TargetingTregs andthe Tumor
Micromilieu in order to Improve
AntitumoralT-Cell Responses
To date, it became very clear that the tumor microenvi-
ronment, consisting of immunosuppressive cells, especiallyJournal of Biomedicine and Biotechnology 11
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Figure 2: Overview of immunosuppressive evasion mechanisms. Tumor cells and tumor-inﬁltrating Tregs and MDSC can employ a
plethora of immunosupressive factors and molecules that impair T-cell function or lead to T-cell anergy and/or apoptosis. Depicted are
immunosuppressive self-inhibitory circuits of activated CTLs and also immunosuppressive mechanisms of tumors.
Tregs, tumor metabolites, and tumor-derived cytokines crit-
ically aﬀects T-cell-mediated immunotherapy. In particu-
lar, immunosuppressive eﬀects of Tregs can nowadays be
minimized by antibody-mediated (i.e., anti-CD25 [191],
anti-GITR [192]) Treg depletion or chemotherapeutic lym-
phodepletion protocols prior to adoptive cell transfer of
T lymphocytes and vaccination approaches. In addition,
blocking antibodies or soluble receptors can be exploited
for the blockade of cytokines that either suppress eﬀector T
cellsdirectlyor actvia macrophagesand MDSCs.Candidates
include for instance TGF-β [102, 109]a n dI L - 1 0[ 193]. A
further promising avenue to increase the eﬀectiveness of
antitumoral T cells might be the antisense oligodeoxynu-
cleotide or siRNA-mediated silencing of TGF-βRI and RII
receptor expression in the tumor-reactive T cells themselves
or the knock down of TGF-β expression at the tumor site,
in particular in Tregs [194]. Indeed a ﬁrst clinical study tar-
geting TGFβ using the antisense oligonucleotide trabedersen
as single agent showed promising results when locally given
in recurrent glioma patients [195]. A clinical phase I study
forsystemicantibody-mediatedblockadeofTGFβisongoing
(see Table 1). It is foreseen that immunosuppressive enzymes
suchasCOX2,IDO,arginase,andnitricoxidesynthetasewill
be targeted by small chemical compounds and used in com-
bination with immunotherapy. In particular, small molecule
inhibitors targeting COX2 and decreasing intratumoral
PGE2 levels showed promising results in preclinical studies
[196].
11. GeneticManipulationof T Cells for
Immunotherapy of Tumors
Finally, T cells can be genetically manipulated to engraft
polyclonal T cells with an additional antitumor speciﬁcity
and/or improved antitumor response. Additional speciﬁcity
can be provided by the engraftment of T cells with a second
TCR recognizing a speciﬁc tumor-associated antigen. In ﬁrst
clinical trials, TCR gene transfer into peripheral blood T cells
has been shown to be feasible and to reprogram polyclonal T
cells towards tumor antigens [197, 198]. Another approach
uses chimeric antigen receptors (CARs), which are fusion
proteins of an antigen-binding moiety, usually an antibody-
derived single chain fragment variable (scFv) speciﬁc to a
surface tumor antigen, linked to an ITAM-bearing signaling
receptor like the CD3 zeta chain [199, 200]. In general, the
useofCARsisadvantageouswhentreatingtumorswithIFN-
γ unresponsiveness or defects in APM as the recognition
of the tumor cell by the engrafted T cell is independent
of MHC presentation. However, for a CAR approach, the
targeted surface antigen should only be expressed on tumor
cells in order to avoid oﬀ-target eﬀects. And indeed, clinical
trials have proven that CARs were safe and oﬀ-target eﬀects
were not apparent when a strong target antigen expression
was restricted to tumor cells [201–203]( Table 1). Further
signals can be provided upon antigen-binding by the incor-
porationofadditionalsignalingsubunitsfromcostimulatory
receptors like CD28 [204], OX40 (CD134) [205], or 4-1BB12 Journal of Biomedicine and Biotechnology
(CD137) [206]. The combined signaling can induce the
expression of anti-apoptotic proteins, sustained prolifera-
tion, inﬂammatory cytokine secretion, and resistance to im-
munosuppression by soluble or cellular components. The
genetic manipulation of T cells can be further extended
by including expression cassettes for homeostatic T-cell
cytokines [207], anti-apoptotic molecules [208], shRNAs
againstT-cellinhibitorymolecules,andchemokinereceptors
[209] to guide T-cell migration to tumor sides.
12. Conclusions
The considerable progress made in understanding the inter-
action between tumor cells and T cells opens avenues for
the development of improved clinical protocols for T-cell-
based immunotherapy. In particular, the development of
therapeutic tools for eﬃcient cross-priming such as TLR
agonists and sustaining antitumoral functions of T cells as
for example modifying self-restricting circuits should enable
rejection of the tumor and should guarantee engraftment of
long-lived memory T cells. To further improve outcomes,
immunotherapy approaches need to be combined with other
therapies that might target various components of tumor
development such as tumor cell metabolism, apoptosis,
angiogenesis, tumor stroma, and inﬂammation to reduce the
immunosuppressive environment shaped by the tumor. Last
but not least recent studies suggest that the immune system
might contribute mechanistically to the clinical eﬃciency
of chemotherapeutic protocols [28, 31] which should be
further pursued in future clinical trials. We envisage that in
future advanced protocols for adjuvant immunotherapy will
complement conventional therapies for the beneﬁt of cancer
patients.
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